Ensem Therapeutics is a drug discovery and development company that leverages its Kinetic Ensemble platform to develop innovative small molecule precision medicines for oncology. The Kinetic Ensemble platform integrates computational and AI deep learning methodologies with advanced experimental techniques to identify non-obvious binding pockets and accelerate structure-based drug design. The company focuses on high-value and difficult-to-drug targets and may expand into genetic disorders and other disease areas. Ensem is led by CEO Sean Cao and is based in Boston, MA. In August 2022 the company raised $67M in a Series A financing, which it intends to use to further advance the Kinetic Ensemble platform and accelerate its R&D pipeline. Participants in the round included Pavilion Capital, Cenova Capital, Mitsui & Co. Global Investment and CBC Group.

Total raised

$67M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2022